i-SENS, Inc. (099190.KQ)
KRW 16060.0
(-3.37%)
KRW 16060.0
(-3.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.7 Billion KRW | -77.02% |
| 2022 | 16.13 Billion KRW | -36.59% |
| 2021 | 25.45 Billion KRW | -5.17% |
| 2020 | 26.83 Billion KRW | 14.57% |
| 2019 | 23.42 Billion KRW | 3.57% |
| 2018 | 22.61 Billion KRW | 43.79% |
| 2017 | 15.73 Billion KRW | -10.42% |
| 2016 | 17.56 Billion KRW | 19.33% |
| 2015 | 14.71 Billion KRW | 1.73% |
| 2014 | 14.46 Billion KRW | -22.4% |
| 2013 | 18.64 Billion KRW | 113.18% |
| 2012 | 8.74 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 680 Million KRW | 2244.83% |
| 2024 Q1 | -338 Million KRW | 86.02% |
| 2024 Q2 | 29 Million KRW | 108.58% |
| 2023 Q2 | 2.76 Billion KRW | -34.46% |
| 2023 FY | 3.7 Billion KRW | -77.02% |
| 2023 Q1 | 4.21 Billion KRW | 428.47% |
| 2023 Q3 | -849.61 Million KRW | -130.76% |
| 2023 Q4 | -2.41 Billion KRW | -184.5% |
| 2022 Q2 | 2.41 Billion KRW | -81.41% |
| 2022 Q1 | 13 Billion KRW | 389.22% |
| 2022 FY | 16.13 Billion KRW | -36.59% |
| 2022 Q4 | -1.28 Billion KRW | -164.04% |
| 2022 Q3 | 2 Billion KRW | -17.13% |
| 2021 FY | 25.45 Billion KRW | -5.17% |
| 2021 Q2 | 8.86 Billion KRW | 27.57% |
| 2021 Q3 | 6.98 Billion KRW | -21.19% |
| 2021 Q1 | 6.94 Billion KRW | -2.56% |
| 2021 Q4 | 2.65 Billion KRW | -61.95% |
| 2020 Q3 | 6.08 Billion KRW | -14.65% |
| 2020 FY | 26.83 Billion KRW | 14.57% |
| 2020 Q4 | 7.12 Billion KRW | 17.22% |
| 2020 Q2 | 7.12 Billion KRW | 9.64% |
| 2020 Q1 | 6.49 Billion KRW | 409.17% |
| 2019 FY | 23.42 Billion KRW | 3.57% |
| 2019 Q4 | -2.1 Billion KRW | -125.17% |
| 2019 Q3 | 8.35 Billion KRW | -30.28% |
| 2019 Q2 | 11.98 Billion KRW | 130.73% |
| 2019 Q1 | 5.19 Billion KRW | -38.34% |
| 2018 Q3 | 6.69 Billion KRW | 55.05% |
| 2018 FY | 22.61 Billion KRW | 43.79% |
| 2018 Q2 | 4.31 Billion KRW | 35.29% |
| 2018 Q1 | 3.19 Billion KRW | -21.21% |
| 2018 Q4 | 8.42 Billion KRW | 25.84% |
| 2017 Q2 | 5.3 Billion KRW | 113.53% |
| 2017 FY | 15.73 Billion KRW | -10.42% |
| 2017 Q1 | 2.48 Billion KRW | -51.56% |
| 2017 Q3 | 3.89 Billion KRW | -26.56% |
| 2017 Q4 | 4.04 Billion KRW | 3.96% |
| 2016 FY | 17.56 Billion KRW | 19.33% |
| 2016 Q2 | 3.54 Billion KRW | -5.35% |
| 2016 Q1 | 3.74 Billion KRW | -19.05% |
| 2016 Q3 | 5.13 Billion KRW | 44.73% |
| 2016 Q4 | 5.12 Billion KRW | -0.18% |
| 2015 Q1 | 2.77 Billion KRW | -24.05% |
| 2015 Q4 | 4.63 Billion KRW | 47.34% |
| 2015 Q2 | 4.16 Billion KRW | 50.24% |
| 2015 Q3 | 3.14 Billion KRW | -24.56% |
| 2015 FY | 14.71 Billion KRW | 1.73% |
| 2014 Q3 | 3.44 Billion KRW | -17.59% |
| 2014 FY | 14.46 Billion KRW | -22.4% |
| 2014 Q1 | 3.19 Billion KRW | -42.06% |
| 2014 Q4 | 3.65 Billion KRW | 6.03% |
| 2014 Q2 | 4.17 Billion KRW | 30.97% |
| 2013 Q1 | 3.18 Billion KRW | -2.96% |
| 2013 Q2 | 4.58 Billion KRW | 43.94% |
| 2013 FY | 18.64 Billion KRW | 113.18% |
| 2013 Q3 | 5.36 Billion KRW | 16.88% |
| 2013 Q4 | 5.5 Billion KRW | 2.72% |
| 2012 Q3 | 2.09 Billion KRW | 0.0% |
| 2012 Q4 | 3.28 Billion KRW | 56.59% |
| 2012 FY | 8.74 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 116.43 Billion KRW | 96.814% |
| InBody Co.,Ltd | 36.72 Billion KRW | 89.9% |
| Curexo Inc. | -4.85 Billion KRW | 176.381% |
| Seegene, Inc. | 669.01 Million KRW | -454.409% |
| Ray Co., Ltd. | -2.14 Billion KRW | 272.81% |
| Gencurix Inc. | -19.26 Billion KRW | 119.258% |
| Sugentech Inc. | -17.23 Billion KRW | 121.516% |
| L&C Bio Co., Ltd | 48.36 Billion KRW | 92.33% |